HighTower Advisors
IBRX icon

HighTower Advisors’s ImmunityBio IBRX Stock Holding History

HighTower Advisors’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$473K Sell
54,068
-1,812
-3% -$13.7K ﹤0.01% 2792
2026
Q1 		$429K Buy
55,880
+22,368
+67% +$153K ﹤0.01% 2854
2025
Q4 		$66.4K Sell
33,512
-13,549
-29% -$30.7K ﹤0.01% 3554
2025
Q3 		$116K Buy
47,061
+13,287
+39% +$34.2K ﹤0.01% 3514
2025
Q2 		$89.2K Buy
33,774
+2,565
+8% +$6.9K ﹤0.01% 3488
2025
Q1 		$93.9K Buy
31,209
+1,114
+4% +$3.38K ﹤0.01% 3374
2024
Q4 		$77K Sell
30,095
-6,517
-18% -$27.1K ﹤0.01% 3415
2024
Q3 		$136K Buy
+36,612
New +$169K ﹤0.01% 3242
2024
Q2 		– Sell
-10,302
Closed -$55K – 3796
2024
Q1 		$55K Buy
+10,302
New +$46.6K ﹤0.01% 3242

Other funds holding IBRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

HighTower Advisors's IBRX Position: Q2 2026 in Review

HighTower Advisors reduced its ImmunityBio (IBRX) stake by 3.2% in Q2 2026, selling an estimated $13.7K and leaving 54,068 shares worth $473K. The position accounts for ﹤0.01% of the portfolio, ranked #2792.

HighTower Advisors first reported a position in IBRX in Q1 2024 and has held it in 9 quarters since. 405 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

  • HighTower Advisors held 54,068 shares of ImmunityBio worth $473K as of Q2 2026.
  • HighTower Advisors sold 1,812 ImmunityBio shares in Q2 2026, an estimated $13.7K.
  • ImmunityBio made up ﹤0.01% of HighTower Advisors's portfolio in Q2 2026, its #2792 holding.
  • HighTower Advisors first reported a position in ImmunityBio in Q1 2024 and has held it in 9 quarters since.
  • 405 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on HighTower Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.